利用树突状细胞：多发性骨髓瘤持久免疫控制的下一个前沿。
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma.
机构信息
Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
Winship Cancer Institute, Emory University, Atlanta, Georgia.
出版信息
Clin Cancer Res. 2023 Nov 14;29(22):4524-4526. doi: 10.1158/1078-0432.CCR-23-2292.
Abstract
Immune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 4575.
摘要
基于免疫的方法，包括 T 细胞重定向，已经改变了骨髓瘤的治疗格局。树突状细胞 (DC) 的注射导致骨髓瘤接种患者中免疫反应的诱导。这些研究为未来利用 DC 增强肿瘤免疫和改善骨髓瘤患者预后的联合策略铺平了道路。详见 Freeman 等人的相关文章，第 4575 页。
相似文献
1
Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma.利用树突状细胞：多发性骨髓瘤持久免疫控制的下一个前沿。
Clin Cancer Res. 2023 Nov 14;29(22):4524-4526. doi: 10.1158/1078-0432.CCR-23-2292.
2
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.胶质母细胞瘤患者自体肿瘤裂解物负载树突状细胞疫苗接种：文献系统评价
Clin Transl Oncol. 2024 Dec 23. doi: 10.1007/s12094-024-03830-9.
3
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
4
Harnessing the immune responses: a new frontier in Ewing sarcoma treatment.利用免疫反应：尤因肉瘤治疗的新前沿。
Med Oncol. 2025 Jun 27;42(8):291. doi: 10.1007/s12032-025-02848-5.
5
Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.树突状细胞负载 HSP70-H22 肽复合物和 CD40L 增强抗肝癌免疫
J Cancer Res Clin Oncol. 2012 Jun;138(6):917-26. doi: 10.1007/s00432-012-1166-6. Epub 2012 Feb 11.
6
The Efficacy of Neoantigen-Loaded Dendritic Cell Vaccine Immunotherapy in Non-Metastatic Gastric Cancer.新抗原负载树突状细胞疫苗免疫疗法在非转移性胃癌中的疗效
Med Sci (Basel). 2025 Jul 11;13(3):90. doi: 10.3390/medsci13030090.
7
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.在同基因J558L BALB/c骨髓瘤模型中，基于抗体将肿瘤坏死因子（L19-TNFα）和白细胞介素-2（L19-IL2）递送至肿瘤相关血管具有强大的免疫和抗癌活性。
J Cancer Res Clin Oncol. 2018 Mar;144(3):499-507. doi: 10.1007/s00432-017-2564-6. Epub 2018 Jan 11.
8
Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.吲哚胺-吡咯2,3-双加氧酶抑制剂1-MT增强树突状细胞-肿瘤融合疫苗的效力
J Cancer Res Clin Oncol. 2008 May;134(5):525-33. doi: 10.1007/s00432-007-0315-9. Epub 2007 Oct 2.
9
Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.用编码 MAGE-A3 基因的重组慢病毒载体转导的树突状细胞诱导抗原特异性免疫应答。
J Cancer Res Clin Oncol. 2014 Feb;140(2):281-9. doi: 10.1007/s00432-013-1552-8. Epub 2013 Dec 10.
10
In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.原位癌疫苗：重新定义肿瘤微环境中的免疫激活
ACS Biomater Sci Eng. 2025 May 12;11(5):2550-2583. doi: 10.1021/acsbiomaterials.5c00121. Epub 2025 Apr 14.
引用本文的文献
1
Immune status and selection of patients for immunotherapy in myeloma: a proposal.骨髓瘤患者的免疫状态和免疫治疗选择：一项建议。
Blood Adv. 2024 May 28;8(10):2424-2432. doi: 10.1182/bloodadvances.2023011242.
本文引用的文献
1
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.生存素树突状细胞疫苗在骨髓瘤患者自体移植后可安全诱导免疫反应并与持久的疾病控制相关。
Clin Cancer Res. 2023 Nov 14;29(22):4575-4585. doi: 10.1158/1078-0432.CCR-22-3987.
2
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.多发性骨髓瘤和前期病变中抗原特异性 T 细胞浸润和空间结构的调控。
J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629.
3
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.多发性骨髓瘤患者接种 3 剂 mRNA 疫苗后对 SARS-CoV-2 变异体的中和能力和 CD8+ T 细胞反应受损：与突破性感染的相关性。
Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173.
4
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.多发性骨髓瘤及前体状态中的免疫系统：免疫治疗和干预的启示和意义。
Am J Hematol. 2023 Mar;98 Suppl 2(Suppl 2):S4-S12. doi: 10.1002/ajh.26752. Epub 2022 Oct 24.
5
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
6
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.树突状细胞的程序性死亡配体1（PD-L1）表达是癌症中T细胞免疫的关键调节因子。
Nat Cancer. 2020 Jul;1(7):681-691. doi: 10.1038/s43018-020-0075-x. Epub 2020 Jun 22.
7
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.PD-L1 与 PD-1 阻断对人类癌症中髓样炎症的差异影响。
JCI Insight. 2020 Jun 18;5(12):129353. doi: 10.1172/jci.insight.129353.
8
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.如何训练你的 T 细胞：克服多发性骨髓瘤中的免疫功能障碍。
Clin Cancer Res. 2020 Apr 1;26(7):1541-1554. doi: 10.1158/1078-0432.CCR-19-2111. Epub 2019 Oct 31.
9
Bone marrow transplantation generates T cell-dependent control of myeloma in mice.骨髓移植可在小鼠中产生依赖 T 细胞的骨髓瘤控制。
J Clin Invest. 2019 Jan 2;129(1):106-121. doi: 10.1172/JCI98888. Epub 2018 Nov 19.
10
TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma.TIGIT 免疫检查点阻断恢复了针对多发性骨髓瘤的 CD8 T 细胞免疫。
Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9.
Zotero 插件